Internal Medicine, Infectious Disease · Shreveport, LA
NPI
1942241708
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2551 Greenwood Rd, Suite 150
Shreveport, LA, 71103
Phone (318) 212-6888
Groups this clinician bills Medicare through
Medicare paid, 2024
$379K
5,900 services
Medicare patients, 2024
552
Average age 73
Drug cost, 2024
$1.3M
1,417 prescriptions
Company payments, 2025
$1,823
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Halim S Abou-Faycal was code 99232 (hospital e&m - subsequent), 4,239 times for 428 patients. In total Halim S Abou-Faycal billed 5,900 services in 20 codes, and Medicare paid $379K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 4,239 | 428 | $59.37 | $252K |
| 99214 Office E&M - Established | Office | 446 | 114 | $92.07 | $41K |
| 99233 Hospital E&M - Subsequent | Facility | 359 | 276 | $89.67 | $32K |
| 99222 Hospital E&M - Initial | Facility | 353 | 288 | $98.93 | $35K |
| 99231 Hospital E&M - Subsequent | Facility | 41 | 21 | $36.99 | $1,517 |
| 99204 Office E&M - New | Office | 27 | 27 | $123.87 | $3,344 |
| 99223 Hospital E&M - Initial | Facility | 26 | 25 | $121.46 | $3,158 |
| 99213 Office E&M - Established | Office | 19 | 14 | $65.60 | $1,246 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 13 | 13 | $32.77 | $426 |
By year: 2022 $434K for 7,342 services; 2023 $444K for 7,050 services; 2024 $379K for 5,900 services.
Medicare prescription drug claims, 2024
In 2024, the drug Halim S Abou-Faycal prescribed most often to Medicare patients was Sodium Chloride (0.9 % Sodium Chloride), with 153 prescriptions and refills. In total Halim S Abou-Faycal wrote 1,417 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sodium Chloride 0.9 % Sodium Chloride | 153 | 153 | 34 | $1,071 |
| Daptomycin Generic | 121 | 121 | 26 | $221K |
| Minocycline Hcl Generic | 121 | 130 | 43 | $3,691 |
| Ertapenem Ertapenem Sodium | 106 | 106 | 25 | $50K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 85 | 85 | 14 | $336K |
| Cefepime Hcl Generic | 57 | 57 | 13 | $4,754 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 51 | 53 | 14 | $251 |
| Cephalexin Generic | 43 | 45 | 18 | $592 |
| Cefadroxil Generic | 41 | 52 | 12 | $1,154 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 41 | 41 | Under 11 | $148K |
| Fluconazole Generic | 36 | 40 | 16 | $1,065 |
| Levofloxacin Generic | 32 | 33 | 17 | $273 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 32 | 33 | 16 | $701 |
| Doxycycline Hyclate Generic | 28 | 29 | 11 | $443 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 25 | 25 | Under 11 | $97K |
Brand drugs: 426 claims; generic drugs: 991 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Halim S Abou-Faycal $1,823 ($1,823 in general payments such as food, travel and fees) from 10 companies. The largest payer was Paratek Pharmaceuticals, Inc. with $377.
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 21 | $377 |
| Abbvie Inc. ABBV | 16 | $315 |
| Melinta Therapeutics, LLC | 11 | $228 |
| ViiV Healthcare Company GSK | 15 | $182 |
| Shionogi Inc 4507.T | 10 | $181 |
| Merck Sharp & Dohme LLC MRK | 10 | $177 |
| Insmed, Inc. INSM | 7 | $142 |
| Theratechnologies Inc. THTX | 3 | $124 |
| Gilead Sciences, Inc. GILD | 4 | $78.63 |
| Aimmune Therapeutics, Inc. | 1 | $18.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.